A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

Currently available antihyperglycemic agents, despite being effective, provide inadequate glycemic control and/or are associated with side effects or nonadherence. Canagliflozin, a widely used orally active inhibitor of sodium-glucose cotransporter 2 (SGLT2), is a new addition to the therapeutic arm...

Full description

Bibliographic Details
Main Authors: K M Prasanna Kumar, Sujoy Ghosh, William Canovatchel, Nishant Garodia, Sujith Rajashekar
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
Canagliflozin
glycated hemoglobin
hypoglycemic agents
pleiotropic benefits
sodium-glucose cotransporter 2 inhibitor
type 2 diabetes mellitus
Online Access:http://www.ijem.in/article.asp?issn=2230-8210;year=2017;volume=21;issue=1;spage=196;epage=209;aulast=Prasanna

Internet

http://www.ijem.in/article.asp?issn=2230-8210;year=2017;volume=21;issue=1;spage=196;epage=209;aulast=Prasanna

Similar Items